{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+ranibizumab+.3+dose", "query": { "intervention": "Intravitreal injection of ranibizumab .3 dose" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 32, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Intravitreal+injection+of+ranibizumab+.3+dose&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T23:05:19.352Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00407355", "title": "Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Macular Edema", "Retinal Vein Occlusion" ], "interventions": [ { "name": "Intravitreal injection of ranibizumab .3 dose", "type": "DRUG" }, { "name": "Intravitreal injection of Ranibizumab .5 dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Peter A Campochiaro, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-01", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00407355" }, { "nct_id": "NCT01397409", "title": "Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Age-related Macular Degeneration" ], "interventions": [ { "name": "AGN-150998", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "Sham Injection", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 271, "start_date": "2011-09-01", "completion_date": "2014-04-30", "has_results": true, "last_update_posted_date": "2019-04-16", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397409" }, { "nct_id": "NCT01884597", "title": "Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PCV", "Polypoidal Choroidal Vasculopathy" ], "interventions": [ { "name": "high-dose ranibizumab", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hawaii Pacific Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "25 Years to 95 Years" }, "enrollment_count": 24, "start_date": "2010-11", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2017-10-09", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 3, "location_summary": "Honolulu, Hawaii • ‘Aiea, Hawaii", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "‘Aiea", "state": "Hawaii" }, { "city": "‘Aiea", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT01884597" }, { "nct_id": "NCT00436553", "title": "Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Macular Degeneration", "Choroidal Neovascularization" ], "interventions": [ { "name": "Verteporfin Photodynamic Therapy", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Verteporfin Placebo", "type": "DRUG" }, { "name": "Ranibizumab Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 321, "start_date": "2007-02", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-04-19", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 36, "location_summary": "Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00436553" }, { "nct_id": "NCT03038880", "title": "Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascularization, Choroidal", "Macular Degeneration, Age-Related" ], "interventions": [ { "name": "Faricimab", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Sham Procedure", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 76, "start_date": "2017-01-27", "completion_date": "2018-03-29", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Campbell", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03038880" }, { "nct_id": "NCT02050828", "title": "The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema (DME)" ], "interventions": [ { "name": "AKB-9778", "type": "DRUG" }, { "name": "ranibizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Sham", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aerpio Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 144, "start_date": "2014-01", "completion_date": "2015-05", "has_results": false, "last_update_posted_date": "2017-03-16", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 39, "location_summary": "Pheonix, Arizona • Tucson, Arizona • Arcadia, California + 35 more", "locations": [ { "city": "Pheonix", "state": "Arizona" }, { "city": "Pheonix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02050828" }, { "nct_id": "NCT01982435", "title": "Safety and Efficacy of Ranibizumab for Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Justis Ehlers", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2014-06-24", "completion_date": "2016-05-26", "has_results": true, "last_update_posted_date": "2020-11-03", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 2, "location_summary": "Cleveland, Ohio • Mayfield Heights, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Mayfield Heights", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01982435" }, { "nct_id": "NCT01610557", "title": "Ranibizumab and Bevacizumab for Diabetic Macular Edema", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema" ], "interventions": [ { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Eye Institute (NEI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2012-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2022-12-09", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01610557" }, { "nct_id": "NCT04567303", "title": "Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Macular Degeneration" ], "interventions": [ { "name": "Zifibancimig", "type": "DRUG" }, { "name": "Ranibizumab", "type": "DRUG" }, { "name": "Port Delivery Platform", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 177, "start_date": "2020-10-28", "completion_date": "2026-08-25", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 36, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Encino, California + 32 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04567303" }, { "nct_id": "NCT02543229", "title": "Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Eye Diseases", "Macular Degeneration", "Retinal Diseases", "Retinal Degeneration", "Neovascularization, Pathologic" ], "interventions": [ { "name": "OPT-302", "type": "DRUG" }, { "name": "Lucentis™", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Opthea Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 51, "start_date": "2015-07", "completion_date": "2017-09", "has_results": false, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-09-29T23:05:19.352Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Maria", "state": "California" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543229" } ] }